Global X Genomics & Biotechnology ETF (GNOM)
| Assets | $67.96M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 6.97M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | -15.11% |
| Volume | 111,663 |
| Open | 9.63 |
| Previous Close | 9.70 |
| Day's Range | 9.63 - 9.93 |
| 52-Week Low | 9.52 |
| 52-Week High | 12.53 |
| Beta | 1.09 |
| Holdings | 42 |
| Inception Date | Apr 5, 2019 |
About GNOM
Fund Home PageThe Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that is based on the Solactive Genomics index. The fund tracks an index of global biotech equities, selected and weighted by market cap. GNOM was launched on Apr 5, 2019 and is issued by Global X.
Top 10 Holdings
45.49% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 5.71% |
| Veracyte, Inc. | VCYT | 5.32% |
| Qiagen N.V. | QGEN | 4.57% |
| Bio-Techne Corporation | TECH | 4.50% |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 4.46% |
| BioNTech SE | BNTX | 4.39% |
| Agilent Technologies, Inc. | A | 4.37% |
| Illumina, Inc. | ILMN | 4.09% |
| Sarepta Therapeutics, Inc. | SRPT | 4.04% |
| BioMarin Pharmaceutical Inc. | BMRN | 4.04% |
News
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment
GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying hold...
Healthcare Dashboard For August And Focus On GNOM
This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value a...
GNOM: A Genomics ETF That Will Have Its Day, Even If Not Right Now
GNOM is a $200 million ETF that invests in a forward-looking set of innovative businesses focused on the genomics industry. This is a long-term growth area, but it will need to get more profitable to ...
GNOM: Healthcare Dashboard For January
Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality.
GNOM: Get Exposure To The Latest Genomics And Biotechnology Companies
The Global X Genomics & Biotechnology ETF tracks the Solactive Genomics Index. It invests in genomics and biotechnology companies. The fund is highly concentrated in one industry, which can negatively...
GNOM: ETF Review And Healthcare Dashboard For October
Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages.
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
GNOM: Poor Historical Performance, Lack Of Focus, Uncertain Future
GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future.
Equity Market Cap For Technologically Enabled Innovation Likely To Grow Exponentially
Investment strategies geared to the future evaluate complex dynamics that can evolve rapidly. As innovation's market share has grown, investment capacity - as measured by average days to trade - also ...
ETF Battles: ARKG Vs IDNA Vs GNOM
Join us for a triple-header to determine the best genomics biotech ETF!
Global X Genomics & Biotechnology ETF: Targeted Fund Provides Strong Growth And Steady Dividend
Global X Genomics & Biotechnology ETF is a passive ETF with a healthcare sector focus.
ETF Battles: ARKG Vs GNOM
Which biotech/genomics ETF is the better play?
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Biotech ETFs surge on vaccine rollout, Alexion-AstraZeneca tie-up
Biotech exchange-traded funds rallied Monday as the rollout of the coronavirus vaccine across America shed a bullish light on the industry. The First Trust NYSE Arca Biotechnology Index Fund jumped 4%...
Three tech subgroups can keep climbing despite the sector's record run, ETF analyst says
Investors should consider buying into genomics, cloud computing and video gaming ETFs as tech trades near records, Global X's Jay Jacobs says.
3 Genomics ETFs Worth Jumping For
The scramble to bring a coronavirus vaccine to market is lifting the health care sector this year as a slew of biotechnology and other, more nuanced exchange-traded funds targeting the group are deliv...
Themes For Defensive Positioning
We believe cannabis, infrastructure, genomics and longevity are a few themes that could not only withstand a potential recession, but also perhaps thrive.
This High Growth ETF May Not Be As Pricey As You Think
When it comes to growth stocks, investors often expect they will pay up to access that.